Hypocholesterolemic Effect of Fibracep
FIBRACEP
Validation Study of the Effects of FIBRACEP Supplementation on the Lipid Profile
1 other identifier
interventional
90
1 country
1
Brief Summary
FIBRACEP is an onion based fiber that has demonstrated in vitro and in animal models the capacity to increase HDL cholesterol levels as well to improve other lipid profile species. This intervention aims to demonstrate FIBRACEP's blood lipid profile improvement effect. For that purpose, hypercholesterolemic subjects will be recruited and given a daily dose of 7 g of FIBRACEP for two months. Changes in blood lipid profile will be the end-point of the study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started May 2015
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2016
CompletedFirst Submitted
Initial submission to the registry
September 2, 2020
CompletedFirst Posted
Study publicly available on registry
September 11, 2020
CompletedSeptember 11, 2020
September 1, 2020
1 year
September 2, 2020
September 10, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Blood HDL-cholesterol
Cholesterol content in HDL lipoproteins determined by nuclear magnetic resonance
2 months
Secondary Outcomes (3)
Blood lipid profile
2 months
Blood lipoprotein number
2 months
Blood lipoprotein size
2 months
Study Arms (3)
Insoluble Fibre
ACTIVE COMPARATORCookies with insoluble fibre (wheat bran)
Soluble Fibre
ACTIVE COMPARATORCookies with soluble fibre (Psyllium plantago)
FIBRACEP
EXPERIMENTALCookies with FIBRACEP
Interventions
A total intake of 7 g/day of FIBRACEP (provided in 6 cookies of 15 g/each) during two months
A total intake of 7 g/day of wheat bran (provided in 6 cookies of 15 g/each) during two months
A total intake of 7 g/day of psyllium plantago (provided in 6 cookies of 15g/each) during two months
Eligibility Criteria
You may qualify if:
- Total cholesterol levels above 200 mg/dL, observed in at least 3 different days
- Body mass index between 25 and 35 (Overweight and obesity type 1 diagnosis)
You may not qualify if:
- Type 1 and Type 2 Diabetes
- Allergy to any compound described in FIBRACEP
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
José Serrano Casasola
Lleida, 25198, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
September 2, 2020
First Posted
September 11, 2020
Study Start
May 1, 2015
Primary Completion
May 1, 2016
Study Completion
May 1, 2016
Last Updated
September 11, 2020
Record last verified: 2020-09
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR
- Time Frame
- January 2021, for 2 years.
- Access Criteria
- By e-mail to Principal Investigator, who will decide to share the data if fulfill research purposes.
By request to Principal Investigator